RESUMEN
Taking into account the information about the role of insulin-like growth factor -1 (IGF-1) in breast cancer the main aim of the present study was to investigate the cellular immune response to IGF-1. There were examined 58 patients with breast cancer (61 +/- 1 years, BMI 31,2 +/- 0,9 kg/m2, all postmenopausal) and 10 with benign tumors of the breast (56 +/- 2 years, BMI 30,8 +/- 0,7 kg/m2 all menopausal) as well as 17 patients suffering from cancer of different sites. Sensibilization of lymphocytes to IGF-1 was measured in the reaction of blast transformation of peripheral blood lymphocytes. The majority of breast cancer patients (47/58) revealed the sensibilization of peripheral blood lymphocytes to IGF-1. Thus in a part of patients (29 /47) this reaction was suppressed and revealed after suppression of cyclooxygenase and/or blocking of the histamine H2-receptors by corresponding pharmaceutics drugs in vitro.
